FDA Grants Breakthrough Therapy Designation to Gene Therapy for Cerebral Adrenoleukodystrophy – AJMC.com Managed Markets Network
|
FDA Grants Breakthrough Therapy Designation to Gene Therapy for Cerebral Adrenoleukodystrophy
AJMC.com Managed Markets Network The FDA has granted a Breakthrough Therapy designation to bluebird bio, Inc’s Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), an X-linked genetic disorder caused by a defect in the gene ABCD1. This mutation results in … |
|
FDA Grants Breakthrough Therapy Designation to Gene Therapy for Cerebral Adrenoleukodystrophy
AJMC.com Managed Markets Network The FDA has granted a Breakthrough Therapy designation to bluebird bio, Inc’s Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), an X-linked genetic disorder caused by a defect in the gene ABCD1. This mutation results in … |
Financial Times |
Merck cements its position as dominant developer of immunotherapy
Financial Times Merck cemented its position as the dominant developer of immunotherapy after a large clinical trial showed lung cancer patients taking its drug lived for longer than those on chemotherapy. Immunotherapy drugs, which work by encouraging the body’s … Lung Cancer Drug From Merck Solidifies Lead in Crowded FieldBloomberg Cancer Drug Keytruda a New Weapon Against Advanced Lung TumorsU.S. News & World Report |
|
Cancer conference focuses on immunotherapy
NHK WORLD Research on using the immune system to treat cancer is attracting interest at the world’s largest conference on the disease. About 40,000 people, including doctors and cancer patients, are attending the annual meeting of the American Society of … |